Induction and Maintenance Regimen with Peptide Receptor Radionuclide Therapy (PRRT) Lu-177-DOTA-TATE (Lu-177) in Patients with Advanced Neuroendocrine Tumours (NET).

#1527

Introduction: PRRT using Lu-177 is a treatment option for advanced NETs.

Aim(s): We hypothesize long-term and ongoing therapy with Lu-177 improves outcomes, is effective and safe for these patients. We evaluated toxicities of a Lu-177 regimen of induction (4 cycles of 5.6 GBq every 10 weeks) and maintenance (up to 8 cycles of 3.7 GBq given ≈6 monthly).

Materials and methods: Of 184 NET patients treated with Lu-177, 126 had <6 cycles (9 withdrawn; 117 ongoing), 58 had ≥6 cycles (6-7 cycles; n=27; 8–9; n=18; 10-11; n=13). In 58, the primary included: PNET (n=21), GNET (n= 27), likely GNET (n=3), other (n=7). Cumulative mean administered dose was 28.8 ± 4.5 GBq for 6-7 cycles, 35.7 ± 3.6 GBq for 8-9 and 44.5 ± 6.4 GBq for 10–11.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Mc Ewan A, Wieler M, Makis W, McMullen T, Morrish D,

Keywords: neuroendocrine, Lu-177-DOTA-TATE,